Literature DB >> 378348

Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study of Cancer and Leukemia Groupe B.

G Falkson, H C Falkson, O Glidewell, V Weinberg, L Leone, J F Holland.   

Abstract

One hundred fifty-seven premenopausal women with metastatic breast cancer were prospectively randomized to treatment consisting of oophorectomy + vincristine, prednisone, cyclophosphamide, methotrexate, 5-fluorouracil (VPCMF) (Reg. I) or oophorectomy + cyclophosphamide (Reg. II) or oophorectomy followed by an observation period (Phase 1), followed by VPCMF (Phase 2) (Reg. III). Complete plus partial response rates were 72% on Reg. I, 65% on Reg. II, 18% on Reg. III, Phase 1 and 50% on Reg. III, Phase 2. Median duration of response for Reg. I was 17 months, for Reg. II 16 months, and for Phase 1 and Phase 2 of Reg. III, respectively, 5 months and 8 months. The response rate for patients treated with oophorectomy plus chemotherapy is significantly higher than the response rate achieved with oophorectomy alone as first treatment following the appearance of metastases in premenopausal women.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378348     DOI: 10.1002/1097-0142(197906)43:6<2215::aid-cncr2820430609>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.

Authors:  Y Ogasawara; H Doihara; K Shiroma; Y Kanaya; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.

Authors:  J M Bennett; P Byrne; A Desai; C White; R DeConti; C Vogel; E Krementz; F Muggia; J Doroshow; D Plotkin
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 3.  Update on cancer chemotherapy: general considerations and breast cancer. Part II.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-09       Impact factor: 1.798

4.  Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.

Authors:  F Cavalli; M Beer; G Martz; W F Jungi; P Alberto; J P Obrecht; B Mermillod; K W Brunner
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-01

Review 5.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

Review 6.  Single agent versus combination chemotherapy for metastatic breast cancer.

Authors:  Sue Carrick; Sharon Parker; Charlene E Thornton; Davina Ghersi; John Simes; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.